Lois Dwira, Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 94 Connecticut Blvd, East Hartford, CT 06108 Phone: 860-610-6387 |
Nathalie Marie Mcconnell, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 94 Connecticut Blvd, East Hartford, CT 06108 Phone: 860-528-1359 |
Cynthia Goetz, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 94 Connecticut Blvd, East Hartford, CT 06108 Phone: 860-528-1359 Fax: 860-290-4142 |
Samantha Tamulis, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 94 Connecticut Blvd, East Hartford, CT 06108 Phone: 860-528-1359 |
News Archive
An online relapse prevention tool for Bipolar Disorder offers a "cheap accessible option" for people seeking support following treatment, say researchers.
Physical, sexual and emotional abuse among young gay black men is a pervasive problem, yet there remains a lack of social services and resources available to help them, a Michigan State University scholar argues in a new study.
Truck drivers who have obstructive sleep apnea and who do not attempt to adhere to a mandated treatment program have a fivefold increase in the risk of a severe crash, according to a new study co-authored by Virginia Tech Transportation Institute researchers and featured in the March 21 online edition of the journal Sleep.
A unique examination of one treatment center's use of magnetic resonance imaging (MRI) in new breast cancer patients has found MRI to be superior to mammography in finding additional tumors in a breast in which cancer has already been diagnosed, and in detecting new tumors in a patient's supposedly healthy breast.
The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease.
› Verified 8 days ago